Qiagen N.V. (ETR:QIA)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.03B -7.7% |
| Revenue (ttm) | 1.84B +3.0% |
| Net Income | 358.27M +9.6% |
| EPS | 1.72 +10.4% |
| Shares Out | n/a |
| PE Ratio | 23.10 |
| Forward PE | 17.63 |
| Dividend | 2.27 (5.73%) |
| Ex-Dividend Date | Jul 7, 2026 |
| Volume | 709,928 |
| Open | 40.20 |
| Previous Close | 40.80 |
| Day's Range | 39.00 - 40.23 |
| 52-Week Range | 27.56 - 47.60 |
| Beta | 0.63 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 26, 2026 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purif... [Read more]
Financial Performance
In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.
Financial numbers in USD Financial StatementsNews
Qiagen announces new AI capabilities for researchers
Qiagen (QGEN) announced new artificial intelligence capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible...
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help r...
Barclays upgrades Qiagen to Overweight ahead of Q3 report
Barclays upgraded Qiagen (QGEN) to Overweight from Equal Weight with a price target of $55, up from $40. The tool sector is positioned for accelerating growth amid “conservative” growth estimates…
Qiagen upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Qiagen (QGEN) to Overweight from Equal Weight with a price target of $55, up from $40.
Qiagen: QIAstat-Dx bloodstream infection portfolio now available to U.S. labs
Qiagen (QGEN) announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. FDA. The new panel detects…
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete ...
Qiagen launches QIAmini
Qiagen (QGEN) announced the launch of QIAmini, a compact automated sample preparation system designed to give research laboratories a time-saving and cost-efficient alternative to processing samples b...
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample prepa...
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at ...
Qiagen attracts interest from KKR, Advent, TPG, Manager Magazin reports
Qiagen (QGEN) is attracting interest from multiple private equity firms, including KKR (KKR), EQT, Advent, TPG (TPG), and Bain Capital, with expectations that shareholders may demand at least $50/shar...
Qiagen Transcript: 2026 Global Healthcare Conference
Leadership transition emphasizes R&D and commercial execution, with a strategic review nearing completion. Diagnostics and sample technologies are rebounding, driven by automation and new product launches. Growth is expected to accelerate in Q4, with key opportunities in organic growth and innovation.
Qiagen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership is focused on growth, margin expansion, and commercial execution, with AI and automation initiatives advancing across product lines. Early-stage product launches and the Parse acquisition are driving optimism, while efficiency programs and strong capital allocation support margin targets. Strategic review is ongoing, but the current plan emphasizes standalone growth.
Qiagen price target raised to EUR 42 from EUR 40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Qiagen (QGEN) to EUR 42 from EUR 40 and keeps an Overweight rating on the shares.
Qiagen initiated with a Neutral at UBS
UBS analyst Doug Schenkel initiated coverage of Qiagen (QGEN) with a Neutral rating and $47 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS…
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life sc...
Qiagen announces commercial launch of QIAsymphony Connect
Qiagen (QGEN) announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more ...
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-co...
Qiagen appoints Jonathan Pratt as CEO, effective Sept. 1
09:47 EDT Qiagen (QGEN) appoints Jonathan Pratt as CEO, effective Sept. 1
Qiagen says Thierry Bernard to step down as CEO, to be succeeded by Jon Pratt
QIAGEN (QGEN) announced that Jonathan M. Pratt has been appointed CEO, effective September 1, 2026. Pratt most recently served as President and CEO of Filtration Group, leading the business through…
Qiagen reaffirms Q3, FY26 outlook
QIAGEN (QGEN) remains focused on delivering solid profitable growth by advancing its growth pillars, improving operating efficiency and allocating capital to the highest-return opportunities.
Qiagen: Board continues to evaluate opportunities as part of strategic review
The company said that the Supervisory Board continues to evaluate opportunities, with independent financial and legal advisors, as part of its strategic review to create value for shareholders and oth...
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effect...
Qiagen trading halted, news pending
09:38 EDT Qiagen (QGEN) trading halted, news pending
Qiagen gets FDA clearance for first QIAstat-Dx Bloodstream Infection Panel
QIAGEN (QGEN) announced that the U.S. Food and Drug Administration has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.